Haemophilia in the developing countries: the Iranian experience

Peyman Eshghi1, Mitra Mahdavi-Mazdeh2, Mehran Karimi3, Mohammad Aghighi4

Abstract

Introduction: Management of haemophilia and inherited bleeding disorders is a major challenge especially in developing countries, because of a shortage or absence of products, the cost and the infrastructural health problems. Development of local expertise which results in an improved outlook and reduction in mortality and morbidity in these countries can be helpful for advocates in other developing countries. However, very little information on demography and organizational models for haemophilia care in developing countries are available in the literature. Our aim is a comprehensive report of haemophilia status and its management in Iran.

Material and methods: The Management Center of Transplantation and Special Diseases (MCTSD) of the Ministry of Health of Iran decided to carry out a complete review and compilation of all of the published or available data about patients with haemophilia (PWH) in Iran: their health status, their management planning, organizations, treatment products, facilities and care problems during 2007.

Results: 6496 patients with congenital bleeding disorders were registered. Most of them had haemophilia A and B and von Willebrand disease (vWD). However, rare bleeding disorders are seen more than expected. Inhibitor development is 14-28%. There are different data about virological status of PWH. Factor products and facilities are fairly available with more than 1.5 units per capita of inhabitant factor consumption.

Conclusions: A national formulary based on facilities of the country should be considered and followed by collaboration among the Ministry Of Health, universities and non-governmental organizations.

Key words: Iran, haemophilia care, developing world.

Introduction

New advances in haemophilia treatment such as virally safe factor concentrates and a comprehensive approach to patients have improved the life expectancy as well as the quality of life for haemophiliacs, especially in the last 3 decades [1, 2]. However, treatment options vary around the world. There is wide variability not only in the types of products used (plasma, cryoprecipitate, plasma derived factor concentrates and recombinant factor concentrates) but also in the doses administered...
(minimal to very high) for similar indications [3-5]. In developed countries, accurate diagnosis and treatment based on early recognition of the disease, carrier detection, antenatal diagnosis, standard treatment, prophylaxis, home therapy, early treatment of bleeding episodes, sustained replacement therapy with virally safe clotting factor concentrates, and establishment of comprehensive care centres with a multidisciplinary team resulted in significant effects on patients’ general health, quality of life and survival. Also the haemophilia community request resulted in receipt of support for networks of haemophilia treatment centres (HTCs) from governments [6, 7].

At the same time, in the developing world (with almost 80% of the haemophilia population, who benefit from only 20% of the world’s total haemophilia care budget), development of local expertise resulted in an improved outlook and reduction in mortality and morbidity in spite of a shortage or absence of factor products [8, 9]. However, very little information on demography and organizational models for haemophilia care in developing countries, and also on the types of products being used for factor replacement and the doses being administered for control or treatment of bleeding in different countries, are available in the literature [5, 10-12]. In this study the current situation and the developed plan for the

"Hemophilia Care Program in Iran" will be reviewed to document these data in comparison with other countries.

**Iranian Haemophilia Services Organization**

Iran is a Middle Eastern country comprising 30 provinces and covering an area of 1.648 million square kilometres. The population is around 70 million, life expectancy is 69.96 years [13] and the gross national product (GNP) is reported to be 2767 US$ per capita in 2005 [14].

Haemophilia management in Iran was organized in Imam Khomeini hospital of Tehran University of Medical Sciences in the early 1960s, and it has been the main centre for haemophilia care until now. Although the Ministry of Health (MOH) has been the sponsor of management of haemophilia during the last 40 years, a turning point came in 2001, when the MOH established official relations with haemophilia and thalassaemia treatment and management programmes in addition to dialysis and transplantation through the Management Center of Transplantation and Special Diseases (MCTSD) (Figure 1). The organization was responsible not only for the provision of necessary products and services through the undersecretary of Food and Drugs in the Ministry of Health but also in policy making and strategic planning to achieve

![Figure 1. MOH Organization](image-url)
and establish higher standards of treatment. Throughout 2001-2003, a major function of the centre was to assess the situation of treatment and correction of data. Recognizing the importance of a national haemophilia programme, MCTSD created a national haemophilia committee, composed of physicians who were experts in the treatment of haemophilic patients. As recommended by the World Federation of Hemophilia (WFH), the mission of this committee was the introduction of specific and practical programmes to be used as tools to further treatment of haemophilia and related disorders [15], which covered sensible dosing and equitable distribution of resources to gain the maximum benefit from scarce resources.

In Iran, at present, 41 medical universities are responsible for implementing different treatment and prevention programmes of the Ministry of Health in all the provinces. In each university, one is to oversee and coordinate affairs of haemophilia, thalassaemia, haemodialysis and transplanted patients in different wards which are covered by that special university and are in direct contact with the MCTSD. The data gathering for the national registry is done by these teams for the centre for administrative issues. Collection of data is the mandatory tool, and the budget designation is on the basis of correct information. After 3 years, the MCTSD with participation of pundits is going to develop a “comprehensive national database” which will be offered on-line to all universities in 2007.

There are also several non-governmental organizations, engaged in the field of haemophilia in Iran, such as the Iranian Hemophilia Society, the Iranian Pediatric Hematology and Oncology Society (IPHOS), and the Charity Foundation for Special Diseases. Haemophilia care units which are affiliated to the MOH in Iran in many provinces are managed with such collaboration among them, universities' staffs and hospitals being under the provision of the MCTSD.

Non-profit organizations play an important role in solving public problems, creating more competitive environments for securing charitable support and strengthening public infrastructures. The Iranian Hemophilia Society (IHS) was established in 1967 by government authorities [16, 17]. Their main objectives were social support and contribution in education of haemophilic patients (in face-to-face classes or through brochures and CDs). They have 21 branches with 100 staffs throughout the country [17]. They have also developed a patient registry database to collect information about haemophilic patients and their families [18]. They are also committed to improving patients’ access to treatment facilities and have constructed a part-time out-patient clinic with a well equipped coagulation laboratory in Tehran since 2001.

Material and methods

In this study, the MCTSD of the MOH of Iran, which has the main responsibility for the treatment of haemophilia through 41 medical universities and their related clinics around the country (as the main and original sources of haemophilia data in Iran), carried out a complete review and gathered all of the published or available data about patients with haemophilia (PWH) in Iran: their health status, their management planning, organizations, treatment and care problems during 2007.

Results and Discussion

Frequency and prevalence

There are 6496 cases with congenital bleeding disorders who were registered by the MOH of Iran by December 2006, so the prevalence was estimated at about 9.18 per 100,000. Among them, there are 3957 (61%) FVIII deficiency haemophilia A (frequency of severe, moderate and mild haemophilia A were 47, 33 and 20% respectively). The prevalence of registered congenital bleeding disorders – including congenital platelet function abnormalities [19] – in Iran is shown in Figure 2. Also, regarding the poor availability of diagnostic facilities in most of the centres, the majority of registered cases of von Willebrand Disease (VWD) are symptomatic with frequent medical therapies (mainly type 3) [20], and definite classification for most of the others has not been possible. Although according to the WFH’s survey, the rate of diagnosis of persons with haemophilia is directly related to the economic income of the region, it is worth noting that the number of detected haemophilia A and B (~65 cases per million inhabitants) cases is much higher than expected based on the GNP of Iran in 2005 (2767$) (Table I) [12, 14, 21].

Figure 2. Frequency of congenital bleeding disorders in Iran
positive haemophiliac patients has been reported ribavirin by the MOH [38]. The prevalence of HIV
86

Peyman Eshghi, Mitra Mahdavi-Mazdeh, Mehran Karimi, Mohammad Aghighi

pegylated interferon
haemophiliacs with HCV infection were treated with

[33-37]. During winter 2006 to 2007, 400
comparison with some other countries is low
expected prevalence of HCV Ab positivity in

14 cases (4%) were high responders [27]. The MCTSD
had developed factor VIII inhibitor; among them
14 cases (4%) were high responders. Inhibitor developed in 22, 9.4
and 3.5% of severe, moderate and mild HA
respectively [26]. In another study, 100 cases out of
355 patients (28.1%) from six main haemophilia
care centres in the east and south of Iran in 2005
had developed factor VIII inhibitor; among them
14 cases (4%) were high responders [27]. The MCTSD
is going to establish a routine screening test in all
of the centres by improving their diagnostic facilities.

Blood-borne infections
Another important issue is virological status in
haemophiliacs. Hepatitis C virus (HCV) is the current
major virological problem in haemophilic patients. Since
1995, more careful donor selection and pre-
transfusion screening of blood donors for anti-HCV
has been implemented in all blood banks. According
to unpublished official data of the MCTSD from
9 medical universities around Iran, 773 out of 3282
cases with all congenital bleeding disorders were
anti-HCV positive. The prevalence of HCV infection in
Iranian haemophilic patients has been reported
from 15.6% in Fars, a southern district of Iran, to
76.7% in North-West Iran in different studies, as
reviewed by Allavian et al. [28]. The prevalence of
HBS-Ag positive cases has been reported in < 1%
(2/277), 2.8% (5/171), 27% (27/101) and 4.9% (4/81)
of patients in different studies [29-32]. The overall
expected prevalence of HCV Ab positivity in
patients with haemophilia in Iran is 21%, which in
comparison with some other countries is low
[33-37]. During winter 2006 to 2007, 400
haemophiliacs with HCV infection were treated with
pegylated interferon α alone or in combination with
ribavirin by the MOH [38]. The prevalence of HIV
positive haemophilic patients has been reported
as 0.36% (1/277), 2.3% (4/176) and 19% (69/368) in
different groups and in different periods of time
[29-31, 39].

Quality of life
The most common symptoms influencing the
quality of life in Iran [40] and other developing
countries are still haemarthrosis, haematomas and
epistaxis [10-12]. Fortunately, in last decade,
chemical and radioisotopic synovectomy have been
performed successfully in Imam Khomeini Hospital
between 2002 and 2006. Mortazavi et al. performed
66 radioisotopic synovectomy procedures in
53 patients. It effectively reduced the intra-articular
bleeding rate and factor concentrate use [41].

Treatment and diagnostic facilities
Transfusion and blood bank
During the 1960s, Iranian haemophilic patients
were treated mainly with plasma supplied by
commercial agents who relied mostly on paid blood
donors. After establishment of the Iranian
Blood Transfusion Organization (IBTO) in 1974 as
a governmental non-profit organization for cen-
tralized and scientific activities in transfusion,
cryoprecipitate and fresh frozen plasma were
available gradually for them [42]. In order to provide
a safe plasma product for them, in addition to strict
donor selection, donated blood underwent serologic
tests for HBV, HCV (since 1995), HIV and syphilis. The
IBTO is now considering implantation of a nucleic
test (NAT) system in its screening protocol [42].
In order to supply the Iran pharmaceutical market
with plasma derived products, the IBTO started a toll
fractionation programme in 2004. After verification
of the quality system of Iranian blood collection
centres by the Paul-Ehrlich Institute (as a reputable
EU authority) in 2005, toll fractionation of about
70,000 l of plasma in France and Germany to 300 kg
of IVIG, 10 MIU FVIII, 14 MIU FIX, and 1800 kg
albumin has been established [42, 43].

Products and protocols
Over the past 2 decades, MOH has been
responsible for the acquisition and distribution of
concentrated factor products in Iran. These products
include plasma derived factor VIII concentrates
(FVIII: C) and factor IX concentrates (FIX: C,
prothrombin complex (PCC), activated PCC (APCC),
and recombinant FVIIa (and recently VWF)
concentrates and subcutaneous desmopressin for
2007 (Figure 3). After establishment of the MCTSD
in the early 2000s, a regular programme has
recently been started which planned the acquisition
of concentrated factor as IU per patient per year
and initiated distribution to the various states
according to the number of patients registered in each state. Recently a national scientific and cost-effective formulary has been prepared by the Thalassemia and Hemophilia Committee of the MCTSD according to recommendations of the WFH and reliable international references [2, 8, 10, 15, 44, 45].

In this manner, although the total health expenditure of GDP is 6% [7] in 2006 the budget designation for importation of coagulating factors was about 50,000,000 US$ (20% of the whole subsidy budget of the Ministry of Health) and factor VIII was supplied at the rate of 1.5 units per capita of inhabitant (and 2 units per capita of inhabitant in 2007), in contrast with many other developing countries. From March 2006 to March 2007, the reported consumption of factor concentrates nationwide was: FVIII: C, 107 500 000 IU; FIX: C, 17 000 000 IU; APCC 3 250 000 IU; and rFVIIa 46 800 mg. The total cost of care of patients including products, routine diagnostics and treatment services are paid by the insurance system and the Ministry of Health in Iran. In one study in the Fars province of Iran, the factor cost was 99% of the total cost of care [46], which is high in comparison with the USA, UK and Italy (72, 29 and 32% respectively) [47, 48].

Although on-demand therapy is the current treatment strategy in Iran, it seems that it is time to shift from on-demand to a prophylactic programme or home therapy and better services and follow-ups by establishing comprehensive care centres (CCC) all over the country. At the first step, it would be done as a pilot study in some provinces which have expert haematologists and CCs. A trial programme for home therapies and carrier detection in haemophilia families was set up in Esfahan Province by the Genetic Department of the Center for Disease Control of the MOH in January 2007. It has also been underway in Shiraz Hemophilia Center since 2004. The last but not the least valuable step is developing comprehensive care, followed through education courses for health care professionals who are in centres in service of

<table>
<thead>
<tr>
<th>Table II. Available diagnostic facilities in coagulation laboratory of IBTO (2006)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prothrombin time (PT)</strong></td>
</tr>
<tr>
<td><strong>Mixed prothrombin time (Mixed PT)</strong></td>
</tr>
<tr>
<td><strong>Activated partial thromboplastin time (aPTT)</strong></td>
</tr>
<tr>
<td><strong>Mixed activated partial thromboplastin time (mixed aPTT)</strong></td>
</tr>
<tr>
<td><strong>Thrombin time (TT)</strong></td>
</tr>
<tr>
<td><strong>Reptilase time (RT)</strong></td>
</tr>
<tr>
<td><strong>Kaolin clotting time (KCT)</strong></td>
</tr>
<tr>
<td><strong>dRVVT screen</strong></td>
</tr>
<tr>
<td><strong>dRVVT confirm</strong></td>
</tr>
<tr>
<td><strong>Fibrinogen</strong></td>
</tr>
<tr>
<td><strong>Fibrinogen/fibrin degradation products (FDP)</strong></td>
</tr>
<tr>
<td><strong>D-dimer</strong></td>
</tr>
<tr>
<td><strong>Factor II assay</strong></td>
</tr>
<tr>
<td><strong>Factor V assay</strong></td>
</tr>
<tr>
<td><strong>Factor VII assay</strong></td>
</tr>
<tr>
<td><strong>Factor VIII assay</strong></td>
</tr>
<tr>
<td><strong>Factor IX assay</strong></td>
</tr>
<tr>
<td><strong>Factor X assay</strong></td>
</tr>
<tr>
<td><strong>Factor XI assay</strong></td>
</tr>
<tr>
<td><strong>Factor XII assay</strong></td>
</tr>
<tr>
<td><strong>Factor XIII deficiency screen (Clot solubility test)</strong></td>
</tr>
<tr>
<td><strong>HMWK deficiency assay</strong></td>
</tr>
<tr>
<td><strong>Inhibitor titre of all of the coagulation factors</strong></td>
</tr>
<tr>
<td><strong>Von Willebrand factor function (ristocetin co-factor)</strong></td>
</tr>
<tr>
<td><strong>Von Willebrand factor function (WF collagen binding assay)</strong></td>
</tr>
<tr>
<td><strong>Von Willebrand factor antigen</strong></td>
</tr>
<tr>
<td><strong>Ristocetin induced platelet aggregation (RIPA)</strong></td>
</tr>
<tr>
<td><strong>Clot retraction</strong></td>
</tr>
<tr>
<td><strong>Platelet aggregation (ADP)</strong></td>
</tr>
<tr>
<td><strong>Platelet aggregation (arachidonic acid)</strong></td>
</tr>
<tr>
<td><strong>Platelet aggregation (collagen)</strong></td>
</tr>
<tr>
<td><strong>Platelet aggregation (ristocetin)</strong></td>
</tr>
<tr>
<td><strong>Platelet factor III</strong></td>
</tr>
<tr>
<td><strong>GP Ib/IX (CD 42)</strong></td>
</tr>
<tr>
<td><strong>GP IIb/III (CD 41/CD 61)</strong></td>
</tr>
<tr>
<td><strong>Anti thrombin activity</strong></td>
</tr>
<tr>
<td><strong>Anti thrombin antigen</strong></td>
</tr>
<tr>
<td><strong>Protein S activity</strong></td>
</tr>
<tr>
<td><strong>Total protein S antigen</strong></td>
</tr>
<tr>
<td><strong>Free protein S antigen</strong></td>
</tr>
<tr>
<td><strong>Activated protein C resistance (APC-R)</strong></td>
</tr>
<tr>
<td><strong>Protein C activity</strong></td>
</tr>
<tr>
<td><strong>Protein C antigen</strong></td>
</tr>
<tr>
<td><strong>Lupus anti-coagulant (confirm)</strong></td>
</tr>
<tr>
<td><strong>Alpha2 anti plasmin</strong></td>
</tr>
<tr>
<td><strong>Tissue plasminogen activator (tPA)</strong></td>
</tr>
<tr>
<td><strong>Plasminogen activator inhibitor (PAI)</strong></td>
</tr>
<tr>
<td><strong>Plasminogen</strong></td>
</tr>
<tr>
<td><strong>Factor S Leiden, PCR</strong></td>
</tr>
<tr>
<td><strong>Prothrombin 20210, PCR</strong></td>
</tr>
<tr>
<td><strong>MTHFR, PCR</strong></td>
</tr>
</tbody>
</table>
patients. The guidelines have been published by the MCTSD and officially have been sent to universities to be prepared for them.

Surgical interventions in Iranian patients with haemophilia (PWH), like many others in the developing world, are difficult in the setting of limited availability of factor concentrates on one hand and lack of established international guidelines for factor concentrate prophylaxis for PWH undergoing surgery on the other hand. These recommendations were not established based on large clinical trials and fail to define the safe lower limit of factor concentrate prophylaxis for surgery [4]. Whenever the factor supply is in acceptable amounts for elective surgery (especially orthopaedic surgery and circumcision), it is officially announced.

Diagnosis and prevention

Diagnostic facilities have grown up around the country and now at least 3 well equipped special coagulation and molecular genetics laboratories with expert staffs exist in Iran. The current facilities of the IBTO coagulation laboratory are demonstrated in Table II.

Prenatal diagnosis (PND), a young programme, is an important issue in the comprehensive care of haemophiliacs. As a consequence of technological progress made in this field in Iran, especially during the last 3 years [49], the early detection of an affected fetus through diagnosis of families with a diseased child to reduce incidence with a chance to terminate pregnancy is a young programme in the country. There are two main limitations in this issue. The first is that most Iranians were not familiar with the possibilities afforded by PND for haemophilia [50]. The second is that although there are some passed fatwas (a fatwa is a religious opinion about whether an action is permissible, prohibited, obligatory or disliked) from religious scholars permitting abortion in positive cases, it is not yet legal. The subject is being followed by the MOH.

In conclusion, we argue that treatment of haemophiliacs in the developing countries should be based on at least two aspects. First, a national formulary based on facilities of the country should be considered and followed. As a result, the minimum acceptable standards can be achieved more easily and the next steps become practical. Heterogeneity is risky for any strategic planning. Secondly, cooperation among medical personnel, the government, NGOs and scientific boards must be promoted to establish successful care.

Acknowledgments

We would like to thank Shiraz University of Medical Science for its financial support, Dr. Davood Mehrabani at the Center for Development of Clinical Research of Nemazee Hospital for editorial assistance, and also Shirin Parand at the Hematology Center for editorial assistance.

References

16. Available at: www.hemophilia.org.ir.
18. Tchupan A. Developing a national patient registry Iranian experience. International meeting on challenges on Hemophilia treatment in developing countries. Feb. 5-7 2006, Tehran, Iran.
43. Cheragh-ali A. Plasma fractionation in Iran, international meeting on challenges on hemophilia treatment in developing countries. Feb. 5-7 2006, Tehran, Iran.
46. Karimi M. Health status and costs of care in Iranian hemophilic patients, International meeting on challenges on hemophilia treatment in developing countries. Feb. 5-7 2006, Tehran, Iran.